Lancet Oncology 2000, 1:94–100.PubMedCrossRef 2. Stiller CA, Pritchard J, Steliarova-Foucher E: Liver cancer in European children: incidence and survival, 1978–1997. Report from the Automated Childhood Cancer Information System project. European Journal of Cancer

2006,42(13):2115–23.PubMedCrossRef 3. Weksberg R, Shuman C, Beckwith JB: Beckwith-Wiedemann syndrome. Eur J Hum Genet 2009,18(1):8–14.CrossRef 4. Hirschman BA, Pollock BH, Tomlinson GE: The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. Journal of buy Ulixertinib Pediatrics 2005,147(2):263–6.PubMedCrossRef 5. Zimmermann A: The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. European Journal of Cancer 2005,41(11):1503–14.PubMedCrossRef 6. Zimmermann A: Pediatric liver tumors and hepatic ontogenesis: common and distinctive pathways. Med Pediatr Oncol 2002,39(5):492–503.PubMedCrossRef 7. Honda

S, et al.: Loss of imprinting of IGF2 correlates with CH5183284 clinical trial hypermethylation of the H19 differentially methylated region in hepatoblastoma. British Journal of Cancer 2008,99(11):1891–9.PubMedCrossRef 8. Rainier S, Dobry CJ, Feinberg AP: Loss of imprinting in hepatoblastoma. Cancer Research 1995,55(9):1836–8.PubMed Ro 61-8048 research buy 9. Lopez-Terrada D, et al.: Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol 2009,40(6):783–94.PubMedCrossRef 10. Adesina AM, et al.: Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 2009,40(6):843–53.PubMedCrossRef

11. Jeng YM, et al.: Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 2000,152(1):45–51.PubMedCrossRef Phosphoribosylglycinamide formyltransferase 12. Koch A, et al.: Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999,59(2):269–73.PubMed 13. Wei Y, et al.: Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000,19(4):498–504.PubMedCrossRef 14. Yamaoka H, et al.: Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncology Reports 2006,15(3):551–6.PubMed 15. Taniguchi K, et al.: Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002,21(31):4863–71.PubMedCrossRef 16. Yamaoka H, et al.: Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncol Rep 2006,15(3):551–6.PubMed 17. Blaker H, et al.: Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer 1999,25(4):399–402.PubMedCrossRef 18. Takayasu H, et al.: Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.